Data layers Raw facts Calculated Model prediction AI interpretation

Company Overview

Stock NameJacobson Pharma
Stock Code02633
Company Full NameTo be extracted
IndustryHealthcare
Principal Activities非專利藥及中成藥的開發、生產、市場推廣及銷售,為香港最大的非專利藥公司,產品涵蓋心血管科、中樞神經系統科、腸胃科、口服糖尿藥及呼吸系統科等專科藥,以及保濟丸、飛鷹活絡油等中成藥。
Listing Date2016-09-21
Listing Rules EraOld Rules
Listing Rules ChapterTo be extracted
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)香港九龍觀塘道388號創紀之城1期1座23樓2313-18室
Business Address (Hong Kong)香港九龍觀塘觀塘道388號創紀之城1期1座23樓2313-18室
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitewww.jacobsonpharma.com
Share Registrar卓佳证券登记有限公司 (Tricor Investor Services Limited)
Registrar Contact(852)2980 1333
A-Share/US Dual ListingNo

Offering Information

Offering Mechanism Mechanism A
Offer PriceHK$ 1.50 / shares
Offer Price RangeTo be extracted
Lot SizeTo be extracted
Entry ThresholdTo be extracted
Par ValueRMB 0.01 / shares
Offer Period2016-09-08 to 2016-09-13
Global Offering Shares437,500,000 shares
HK Public Offer Shares (Initial)43,752,000 shares (10.0%)
Public Offer Lots (Initial)To be extracted
International Placing Shares (Initial)393,748,000 shares (90.0%)
Offer Ratio~10.0%
Total Shares Post-IPO1,750,000,000 shares
Greenshoe (Over-allotment Option)Yes
Stabilizing Manager (Greenshoe)To be extracted
Cornerstone Share4.9%
Clawback TiersTo be extracted
Reallocation OptionYes
Total Global Offering SizeHK$ 656,250,000

Stock Connect Inclusion Analysis

26Q4 Regular Review
Inclusion Pathway Regular Path
HK Market Cap HK$ 2.16B
Est. Threshold HK$ 9.39B
Analysis Result HK market cap below threshold, need +334%

Valuation & Financials

Market Cap (at Offer Price)To be extracted
Pre-IPO Valuation (Last Round)Not disclosed
P/E RatioNot disclosed
Profit/Loss Status盈利約152.7百萬港元
Period-End Cash BalanceTo be extracted
Listing Expenses~HK$ 67,100,000
Listing Expenses / Funds Raised~10.22%
Total Pre-IPO InvestmentTo be extracted

Financial Data

Unit: '000 HKD
Income Statement
Item 2014-032015-032016-03
Revenue 926,181947,5911,083,856
Cost of sales -501,339-562,883-596,101
Gross profit 424,842384,708487,755
Other income and gains, net 65,1726,005-465
Selling and distribution expenses -97,974-105,061-133,807
Administrative expenses -169,123-146,810-167,963
Operating profit 222,917138,842185,520
Net finance costs -5,969-2,707-2,523
Profit before tax 216,948136,135182,997
Income tax expense -32,247-22,157-30,335
Profit for the year 184,701113,978152,662
Profit attributable to owners 172,357101,904145,610
Balance Sheet
Item 2014-032015-032016-03
Cash and cash equivalents 131,49270,25882,925
Trade and bills receivables 142,740148,795209,957
Inventories 160,368169,087196,915
Total current assets 444,940394,035499,989
Total assets 1,456,8091,705,2111,822,050
Total current liabilities 488,914650,238816,835
Total liabilities 539,822698,576865,905
Total equity 916,9871,006,635956,145
Equity attributable to owners 877,894957,343906,882
Interest-bearing borrowings 299,576475,629439,335
Cash Flow Statement
Item 2014-032015-032016-03
Net cash from operating activities 150,272161,754221,450
Net cash from investing activities -126,529-390,971-133,723
Net cash from financing activities -8,747160,853-67,586
Net increase in cash 14,996-68,36420,141
Purchase of PP&E -200,391-339,612-134,143
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
First Day CloseHK$ 1.68
First Day OpenHK$ 1.58
First Day Change12.00%
First Day Volume107290000.0
First Day Turnover173359000.0
Use of Proceeds
1、約45%(或270.5百萬港元)用作收購事項; 2、約18%(或108.2百萬港元)用作有關收購、拓展、精簡或提升我們的制造廠房、房產、設施或產能的資本投資; 3、約15%(或90.2百萬港元)用作為專門非專利藥進行生物等效性臨床研究; 4、約12%(或72.1百萬港元)用作在未來五年加大我們的銷售、市場推廣及廣告宣傳力度,以提升品牌的認可度及加強我們產品及業務的品牌忠誠度; 5、約10%(或60.1百萬港元)用作營運資金及其他一般公司用途。

Underwriting Syndicate

Sole Sponsor (1)
中银国际亚洲有限公司 CE AET863
Joint Bookrunners (1)
中银国际亚洲有限公司 CE AET863
Joint Lead Managers (1)
中银国际亚洲有限公司 CE AET863

Cornerstone Investors

#Investor NameInvestment AmountShares Subscribed% of Offer Shares% of Total SharesLock-up PeriodEst. Unlock Date
1 New Heritage Healthcare Limited 49,998,000 HKD — 1.90% — 6 months 2017-03-21
2 香港荣华药业集团有限公司 79,998,000 HKD — 3.00% — 6 months 2017-03-21

Directors & Management

PositionChinese nameEnglish Name
Chairman岑廣業—
Company Secretary黃偉明—
No director data available.

Major Shareholders

Major Shareholders & Holdings緊隨全球發售完成後,Kingshill及Longjin為一致行動方,合共持有本公司約57.58%權益;岑廣業先生透過Kingshill、Queenshill等合共持有約74.78%權益。
About this page

This page shows Jacobson Pharma (02633) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect